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Abstract
Gd-DO3A-diph and Gd-AAZTAC17 are lipophilic mag-
netic resonance imaging (MRI) agents that display
high affinity for low-density lipoprotein (LDL) particles.
However, on binding to LDL, Gd-DO3A-diph shows a
decreased hydration that results in a lower enhance-
ment of water proton relaxation rate. Conversely, Gd-
AAZTAC17 displays a strong relaxation enhancement
at the imaging fields. Each LDL particle can load up to
100 and 400 UNITS of Gd-DO3A-diph and Gd-AAZTAC17,
respectively. Their LDL adducts are taken up by human
hepatoblastoma G2 (HepG2) and melanoma B16 tumor
cells when added to the incubation medium. T1 measure-
ments of the labeled cells indicate that Gd-AAZTAC17 is
significantly more efficient than Gd-DO3A-diph. Further-
more, it has been found that HepG2 hepatoma cells can
internalize higher amounts of Gd-AAZTAC17 than B16
cells and the involvement of LDL receptors (LDLRs) has
been demonstrated in competition assays with free LDL.
Gd-AAZTAC17/LDL adduct proved to be an efficient
probe in the magnetic resonance (MR) visualization of
subcutaneous tumors in animal models obtained by in-
jecting B16 melanoma cells into the right flank of mice.
Finally, confocal microscopy validation of the distribu-
tion of LDL-based probes in the tumor has been ob-
tained by doping the Gd-AAZTAC17/LDL adduct with a
fluorescent phospholipid moiety.
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Introduction
The possibility of designing molecular imaging protocols
based on magnetic resonance imaging (MRI) is very attrac-
tive because of the superb anatomical resolution that is
attainable by this technique. However, MRI suffers from an
intrinsic insensitivity with respect to the competing imaging
modalities. This drawback has to be overcome in designing
suitable amplification procedures based both on the develop-
ment of reporting units endowed with an enhanced sensitivity
and on the identification of efficient routes of accumulation of
imaging agents at the targeting sites [1–3].
The contrast agents which are routinely used in clinical
practice are mainly paramagnetic chelates of Gd3+ ions that
act by enhancing the longitudinal relaxation rate of water
protons (1/T1) in the tissues where they distribute. Much has
been done in the last two decades to identify the structural and
dynamic characteristics of Gd(III) chelates to improve their
relaxivity (r1p = relaxation enhancement of water protons in
the presence of the paramagnetic complex at 1 mM concen-
tration) [4–6]. However, the success of a magnetic resonance
(MR) molecular imaging protocol strongly relies on the ampli-
fication effects associated with the accumulation of the agents
at the cells of interest. A general strategy for achieving this goal
uses nanosized systems such as liposome, micelles, micro-
emulsions, polymers, and so on, to deliver a huge payload of
Gd complexes [7–11]. The nanocarriers are then functional-
ized with the suitable vectors that provide the overall particles
with the required recognition capabilities toward the selected
cellular target. A straightforward extension of this approach
involves the exploitation of naturally occurring nanosized
aggregates such as the different types of lipoproteins [12,13].
These proteins represent an attractive option because they are
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endogenous constituents of blood, consisting of an insoluble
core of cholesterol esters and triglycerides surrounded by a
shell of amphipathic phospholipids and specialized proteins
called apolipoproteins. The low-density lipoproteins (LDLs)
are members of the lipoproteins family and are the main
biological carriers in human plasma of unesterified and es-
terified cholesterol to extrahepatic tissue. The membrane-
associated protein ApoB100 mediates the recognition of the
LDL to its receptor and the subsequent uptake into cells
through receptor-mediated endocytosis [14]. The complex
LDL–LDL receptor (LDLR) is internalized through clathrin-
coated pits, and entrapped into endosomes where LDL
dissociate from the LDLR, which can recycle back to the cell
surface to bind another LDL particle. LDL is then transported
to lysosomes where it is degraded releasing cholesterol that
is used for the synthesis of plasma membrane, steroid
hormones, and bile acids. With a recycle time of 10 minutes
and a lifetime of 24 hours, LDLR efficiently transports many
LDL to LDLR-expressing cells. Among nonmalignant tissues,
liver, adrenal glands, and ovaries make use of the LDLR
system. Altered LDLR levels are found in a variety of
pathological conditions (e.g., atherosclerosis) [15] and sev-
eral tumors overexpress LDLR to supply the high cholesterol
demand of a rapidly dividing cell [16]. In nonmalignant
conditions, high levels of LDLR can be regulated directly by
the physiological cholesterol homeostasis or by pharmaco-
logical intervention. In contrast, such regulation is absent in
tumor-expressing LDLR. In the last few years, there has
been much interest to exploit the LDL transporting system
beyond its biological significance of lipid transport and cho-
lesterol homeostasis to investigate its potential in the diag-
nosis and/or therapeutic delivery of LDL-based drugs to
neoplastic tissues.
Several authors report the use of LDL as carriers for
hydrophobic drugs such as antitumoral drugs [17,18], pho-
todynamic therapy agents [19–21], and imaging probes
[22–28]. Recently, Corbin et al. [29] reported the MRI
visualization of human hepatoblastoma G2 (HepG2) xeno-
graphs in mice using a Gd–diethylenetriaminepentaacetic-
acid (DTPA)–bis(stearylamide) complex able to form strong
adducts with LDL. This work has clearly established that
Gd-loaded LDL particles are very good systems for targeting
tumor cells. Unfortunately, the proposed system displays a
relatively low relaxivity. This drawback is intrinsically related
to the relaxometric properties of the bis-amide Gd3+–DTPA
complex as it has been well established that for this class of
complexes the long exchange lifetime of the coordinated
water quenches any relaxation enhancement that is
expected on formation of slowly moving macromolecular
chelates [30]. Moreover, the use of DTPA bis-amide as
chelating system might not yield to produce sufficiently
stable complexes as it has been shown that Gd-DTPA-
BMA (diethylenetriaminepentaacetic bis-methyl-amide)
system release high amounts of Gd3+ ions in the incubation
medium that are taken up by tumor cells [31]. Finally, the
complexation procedure followed in the work of Corbin et al.
[29] does not guarantee that all the added Gd is sequestered
by the DTPA ligand because the complexation step takes
place when the lipophilic ligand has already been incorpo-
rated in the LDL particle. It might be possible that other co-
ordinating environments, exhibiting even lower stability,
become available on the surface of the particle involving,
for instance, oxygen of the phospholipid heads and/or donor
groups on the amino acid residue of the ApoB100 protein.
On this basis, it was deemed interesting to develop new
Gd-loaded LDL systems characterized by an enhanced
relaxivity and an improved thermodynamic stability of the
Gd-containing cages.
In this study, two novel Gd complexes, namely Gd-DO3A-
diph andGd-AAZTAC17 (Figure 1), containing a hydrophobic
moiety (able to intercalate in the LDL phospholipid mono-
layer) were considered. Both complexes have two coordinated
water molecules (q = 2) in fast exchange with the solvent. The
relaxation enhancement showed by Gd-AAZTAC17 after
binding to fatty acid– free human serum albumin (HSA)
(r1
b(20 MHz, 298 K) = 84 mM1 s1) is by far the highest
relaxivity reported until now for noncovalent paramagnetic
adducts with slowly moving substrates [32]. Furthermore,
LDLs were also loaded with a fluorescent phospholipid ob-
taining a bimodal imaging probe (Figure 2) that allowed as-
sessment of its intracellular localization on amicroscopic level.
Materials and Methods
1H nuclear magnetic resonance (NMR) and 13C NMR spec-
tra were measured with a Bruker AC 200 spectrometer (200
and50.3MHz, respectively) (BrukerBioSpinS.r.l.,Milan, Italy).
Mass spectra were obtained with a VG 7070 EQ spectrometer
(VG Instruments, Manchester, UK).
The longitudinal water proton relaxation rates were mea-
sured on the Stelar Spinmaster spectrometer (Stelar, Mede,
Italy) operating at 20MHz bymeans of the standard inversion-
recovery technique (16 experiments, 2 scans). A typical 90j
pulse width was 3.5 ms and the reproducibility of the T1 data
was ± 0.5%. The 1/T1 nuclear magnetic relaxation dispersion
(NMRD) profiles of water protons were measured over a
continuum of magnetic field strength from 0.00024 to 0.5 T
(corresponding to 0.01–20 MHz proton Larmor frequency) on
the fast field-cycling relaxometer (Stelar Spinmaster FFC
2000; Stelar) equipped with a silver magnet. The relaxometer
operates under complete computer control with an absolute
uncertainty in the 1/T1 values of ± 1%. The typical field se-
quences used were the nonpolarized sequence between
40 and 8 MHz and prepolarized sequence between 8 and
0.01 MHz. The observation field was set at 13 MHz. Sixteen
Figure 1. Schematic representation of Gd-AAZTAC17 and Gd-DO3A-
diph complexes.
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experiments of two scans each were used for the T1 determi-
nation for each field. All starting materials were obtained from
Sigma-Aldrich Co. (St. Louis, MO) and were used without
futher purification.
Gd-AAZTAC17 (AAZTAC17 = 6-bis(carboxymethyl)
amino-4-carboxymethyl-6-heptadecyl-1,4-diazepan-1-yl]acetic
acid) was synthesized according to the previously reported
procedure [32].
Synthesis of Gd-DO3A-diph
N-Phenethyl-2-phenylacetamide (2): 2-Phenethylamine
(2.63 g, 21.7 mmol) was added to a vigorously stirred mixture
of CH2Cl2 (40 ml) and H2O (10 ml), where 2-phenylacethyl-
chloride 1 (3.36 g, 21.7mmol) andNa2CO3 (11.5 g, 108.5mmol)
were previously solubilized. After 8 hours, NaOH (40 ml,
0.5 M) was added and the reaction products were extracted
with CH2Cl2. The organic phase was washed twice with HCl
(0.5 M), dried over Na2SO4, and filtered. Evaporation of the
solvent afforded 4.11 g of compound 2 (79%) as a white
amorphous solid. 1H NMR (200 MHz, CDCl3); d 7.35–7.02
(m, 10H), 5.38 (m, 1H), 3.55–3.42 (m, 4H), 2.77–2.70 (m,
2H), m/z (EI) 239.
Diphenethylamine (3): N-Phenethyl-2-phenylacetamide 2
(1.5 g, 6.26 mmol) was added to a stirred suspension of
NaBH4 (2.37 g, 62.65 mmol) in tetrahydrofolate (20 ml) at
10jC. CH3COOH (3.76 g, 62.61 mmol) was slowly added
dropwise and the reaction was then refluxed for 6 hours.
Water was added (3 ml) and the tetrahydrofolate was re-
moved at reduced pressure affording a white solid, which,
after filtration, was extracted with 3 M HCl (100 ml) and
toluene (3  50 ml). The organic phase was dried with
Na2SO4 and the solvent was evaporated at reduced pres-
sure. The compound 3was isolated as hydrochloride (1.06 g,
75%). 1H NMR (200 MHz, CDCl3) d 2.70–2.77 (m, 4H);
3.01–3.07 (m, 4H); 7.07–7.17 (m, 10H).m/z (FAB) 226 (M+ 1).
4-(Chloromethyl)-N,N-diphenethylbenzamide (4): 4-
(Chloromethyl)benzoyl chloride (0.59 g, 3.12 mmol), diphen-
ethylamine 3 (0.63 g, 2.4 mmol), and Na2CO3 (1.27 g,
12 mmol) were added to a binary phase system constituted
by CH2Cl2 (15 ml) and H2O (5 ml). The mixture was stirred
for 8 hours and was then diluted with H2O and CH2Cl2.
The two phases were separated and the organic phase
was dried with Na2SO4; the solvent was evaporated in vacuo
to afford a crude material which was purified by flash column
chromatography (silica gel, petroleum ether/ethyl acetate
8:2) to give 4 a pale yellow oil (0.53 g, 59%). 1H NMR
(200 MHz, CDCl3) d 7.37–6.88 (m, 14H); 4.60 (s, 2H);
3.83–2.68 (m, 8H). dc 34.97; 33.71; 45.55; 51.16; 46.84;
126.47; 126.70; 128.51; 136.76; 137.70; 138.30; 139.03;
171.25. m/z (EI) 378.
10-[4-(Diphenethylcarbamoyl)benzyl]-1,4,7,10-tetrazacy-
clododecane-1,4,7-triacetic acid tri tert-butyl ester (5): A
suspension of anhydrous K2CO3 (0.39 g, 2.82 mmol),
1,4,7,10-tetrazacyclododecane-1,4,7-triacetic acid tri tert-
butyl ester 5 (0.63 g, 1.23 mmol), and compound 4 (0.46 g,
1.23 mmol) was stirred at 120jC in dry dimethylformamide
(7 ml) for 3 days. The solvent was evaporated under reduced
pressure and the residue was extracted with H2O and
CH2Cl2. The organic phase was dried with Na2SO4 and the
crude material obtained after concentrating the solution was
purified by flash column chromatography (silica gel, CH2Cl2/
MeOH/conc. NH3 9:1:0.1). The pure product 5 was obtained
as an amorphous solid (0.25 g, 24%). 1H NMR (200 MHz,
CDCl3) d 7.54–6.88 (m, 14H); 3.89–2.29 (m, 32H); 1.58–1.46
(s, 27H). dc 27.82; 27.74; 34.95; 33.67; 49.56; 51.20; 46.77;
55.86; 55.52; 59.02; 82.25; 82.75; 126.45; 128.46; 129.79;
136.17; 137.62; 138.23; 171.18; 172.40; 173.41.m/z (EI) 856.
10-[4-(Diphenethylcarbamoyl)benzyl]-1,4,7,10-tetraza-
cyclododecane-1,4,7-triacetic acid (6) (DO3A-diph): A solu-
tion of 5 (0.22 g, 2.62 mmol) in trifluoroacetic acid (12ml) was
stirred for 8 hours at room temperature. The acid was
removed under reduced pressure and the residue was taken
up in methanol (3 ml). Addition of diethyl ether to this solution
led the formation of a precipitate which was collected by
filtration to afford 6 (0.112 g, 62%) as an amorphous pale
yellow solid. 1H NMR (200 MHz, D2O) d 7.35–6.62 (m, 14H);
4.30–2.29 (m, 2H); dc 133.34; 127.46; 141.30; 139.36;
165.31; 164.60; 174.57.m/z (FAB) 688 (M + 1); 710 (M + Na).
10-[4-(Diphenethylcarbamoyl)benzyl]-1,4,7,10-tetraza-
cyclododecane-1,4,7-triacetic acid Gd complex (7) (Gd-
DO3A-diph): An equimolar amount of GdCl3 solution was
slowly added to a 5 mM ligand solution maintaining the pH
value at 6.5 with NaOH. The mixture was allowed to stir
overnight at room temperature, the pH raised to 8.5, and
then the mixture was stirred for 2 hours. Centrifugation at
7000 rpm for 5 minutes at 10jC allowed the separation of
Gd(OH)3 from the solution. The amount of residual-free Gd
3+
ion was assessed by the Orange Xylenol (Sigma-Aldrich) UV
method [33]; the overall Gd contents was determined by 1H
NMR T1 measurement of the mineralized complex solution
(in 6 M HCl at 120jC for 16 hours). Gd3+ concentrations were
determined from a calibration curve obtained with standard
Figure 2. Schematic representation of LDL labeled with Gd-based and fluorescent probes.
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GdCl3 solutions (from 0.01 to 2 mM). Themethod was double-
checked by inductively coupled plasma (ICP) measurements
and an excellent correspondence in quantifying Gd by the two
methods has been found. When the amount of residual-free
Gd3+ ion was higher than 0.3% (mol/mol), an equivalent
amount of ligand was added and allowed to react overnight.
Mass spectrometry yielded very intense molecular peak
at m/z = 863.2, 864.2, 865.2 (M + Na) with an isotopic distri-
bution pattern consistent with the presence of coordinated Gd.
LDL Adducts Preparation
Gd-AAZTAC17 and Gd-DO3A-diph were incubated with
native human LDL (Biomedical Technology, Stoughton, MA)
at 37jC for 2 hours using a complex/LDL molar ratio of 300:1
and 80:1, respectively. The concentration of the Gd com-
plexes was below their critical micellar concentration (CMC)
(0.09 mM) to avoid the binding of the complexes in their
micellar form with the LDL particles. The CMC was deter-
mined by measuring the 1H NMR relaxation rates as a
function of Gd complex concentration as shown in the study
of Gianolio et al. [32]. In fact, self-assembling systems such
as Gd-AAZTAC17 show a variation of the linear slope of the
relaxation rate when the system passes from the monomeric
state to micellar aggregates. The intercept between the two
straight lines (low and high concentration ranges) provides a
good estimate of the CMC value.
The LDL adducts were concentrated to a final volume of
1ml using Vivaspin centrifuge filters (Sigma) (molecular weight
cutoff = 10,000), and the unbound complex was eliminated by
washing three times with 5 ml of PBS in the same tubes. The
final Gd concentration was determined by 1H NMR T1 mea-
surement of the mineralized complex solution (in 6 M HCl at
120jC for 16 hours) and the protein concentration was deter-
mined by a commercial Bradford assay (Biorad, Hercules,
CA). The labeling of LDL with the fluorescent phospholipid
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-n-lissamine
rhodamine B (Avanti Polar Lipids, Alabaster, AL) was carried
out by dissolving 0.075 mmol of the fluorescent phospholipid
(rhodamine-labeled phospholipid (Rdh)) in 2 ml of chloroform.
The lipid was dried under reduced pressure and then hydrated
in 5 ml of 150 mg/ml LDL (Rdh/LDL, 50:1) and heated at 37jC
for 2 hours. Gd-AAZTAC17 was then intercalated in the LDL
containing Rdh as described above.
Size
The hydrated mean diameter of the adducts was deter-
mined using a Malvern dynamic light-scattering spectropho-
tometer (Malvern Instruments, Malvern, UK). All samples
were analyzed at 25jC in filtered (cutoff = 30 nm) PBS
buffer (pH 7).
Cell Culture
Mouse melanoma cell line (B16-F10) and human liver
carcinoma cell line (HepG2) were obtained from the Amer-
ican Type Culture Corporation. The B16 and HepG2 cells
were cultured in RPMI 1640 and minimum essential medium,
respectively; both media contained 4.5 g/l glucose, 10% (v/v)
FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin. The cells were incubated at 37jC in a humid-
ified atmosphere of 5% CO2. At 80% confluency, cells were
trypsinized with 0.1% trypsin and 0.02% EDTA in PBS.
Cell Viability
Cell viability was measured using a colorimetric assays
based on the ability of the cells to cleave tetrazolium salts bymi-
tochondrial dehydrogenases (WST-1, 4-[3-[4-lodophenyl]-2-4
(4-nitrophenyl)-2H-5-tetrazolio-1,3-benzene disulfonate]).
Assays were performed according to the manufacturer’s
instructions (Roche Molecular Biochemical, Mannheim,
Germany). A total of 80,000 B16 and 100,000 HepG2 cells/
well were seeded in 24-well plates in culture medium. The
day after, cells were incubated with the same medium
containing 10% of a lipoprotein-deficient serum (LPDS) to
increase LDLRs’ expression [34]. After 24 hours, cells were
incubated with zero or different concentrations (10, 30, and
60 mg/ml) of Gd-AAZTAC17-LDL, Gd-AAZTAC17, or LDL in
medium containing LPDS. After 16 hours of exposure, cells
were washed twice with PBS before adding the cell prolifer-
ation reagent WST-1, and incubated for 1 hour of shaking at
37jC. Absorbance (A480) was determined using an spectro-
photometer (Cadas 200; Lange, Hegnau, Switzerland). Via-
bility was reported relative to untreated control cells and was
expressed as a percentage of the control value. Experiments
were repeated three times in two replicates.
Uptake Experiments
For the in vitro uptake experiments, about 3  105 of B16
and 5  105 HepG2 were seeded in 6-cm-diameter culture
dishes. The day after, cells were incubated for 24 hours with
culture media added with 10% LPDS to increase LDLR
expression. After 24 hours, cells were incubated for 16 hours
with increasing concentrations of LDL adducts (10–60 mg/ml).
At the end of incubation, cells were washed three times
with 10 ml ice-cold PBS, detached with trypsin/EDTA, and
transferred into glass capillaries for MRI analysis (see be-
low). Gd content of B16 and HepG2 was determined using
inductively coupled plasma mass spectrometry (ICP-MS)
(Element-2; Thermo-Finnigan, Rodano (MI), Italy). Sample
digestion was performed with 2 ml of concentrated HNO3
(70%) under microwawe heating (Milestone MicroSYNTH
Microwave labstation equipped with an optical fiber temper-
ature control and HPR-1000/6M six position high-pressure
reactor, Bergamo, Italy). After digestion, the volume of
each sample was brought to 2 ml with ultrapure water and
the sample was analyzed by ICP-MS. Three replicates of
each sample solution were analyzed. Protein concentration
of each sample was determined from cell lysates by the
Bradford method using bovine serum albumin as standard.
Experimental Mice and Induction of Transplantable Tumors
Adult C57BL/6 mice were maintained in specific pathogen-
free conditions at both the animal facilities of the Depart-
ment of Clinical and Biological Sciences, Turin University,
Italy, and Charles River Laboratories (Calco, Italy). Handling
and all manipulations were carried out in accordance with the
European Community guidelines, and all the experiments
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were approved by the Ethical Committee of the University of
Turin. B16 cells line were cultured as described above and
tumors were generated by subcutaneous injection into the
right flank of 2 105 cells in 0.2 ml PBS. One week after B16
injection, mice developed solid tumor of 3 to 4 mm in diam-
eter and were used for imaging evaluation and/or for the
confocal analysis.
MRI
All MR images were acquired on a Bruker Avance300
spectrometer (7 T) equipped with a Micro 2.5 microimag-
ing probe (Bruker BioSpin). The system is equipped with
two birdcage resonators with 30- and 10-mm inner diame-
ter, respectively.
In vitro The glass capillaries containing about 2  106 cells
were placed in an agar phantom and MR imaging was per-
formed using a standard T1-weightedmultislice multiecho se-
quence (TR/TE/NEX = 200:3.3/8, FOV = 1.2 cm, one slice =
1 mm, in-plane resolution = 94  94 mm).
In vivo Before MRI examination, animals were anesthe-
tized by injecting tiletamine/zolazepam (Zoletil 100; Virbac,
Milan, Italy) 20 mg/kg + xylazine (Rompun; Bayer, Milan,
Italy) 5 mg/kg.
Gd-AAZTAC17 or Gd-AAZTAC17/LDL (300:1) or Gd-
AAZTAC17/Rhd/LDL (300:50:1) (0.06 mmol/kg) was injected
through tail vein injection in groups 1 (n = 7 mice), 2 (n = 10
mice), and 3 (n = 3 mice), respectively.
In groups 1 and 2, MR images were acquired before, 10
and 30 minutes after, and 3, 8, 24, and 48 hours after the
contrast administration using a T1-weighted, fat-suppressed,
multislicemultiecho protocol (TR/TE/NEX=250:3.2:6, FOV=
3 cm, one slice = 1 mm). Fat suppression was performed
by applying a presaturation pulse (90j BW = 1400 Hz) at the
absorption frequency of fat (1100 Hz from water). Group 3
mice were examined by MRI before and 8 hours after Gd-
AAZTAC17/Rhd/LDL administration, then were sacrificed by
intramuscular injection of a lethal dose of anesthesia. Their
tumors were then excised, fixed, and analyzed by MRI and
confocal microscopy. Ex vivo imaging was performed using a
T1-weighted spin echo protocol (TR/TE/NEX = 250:3.2:12,
FOV = 2.6 cm, one slice = 0.7 mm). Two tumors from
untreated mice were analyzed as control.
Imaging Data Analysis and Processing
The mean signal intensity (SI) values were calculated on
a region of interest (ROI) manually drawn on the whole
tumor, and on the muscle, kidneys, and liver, in all intervals
whenever MR imaging was performed. The mean SI mea-
sured was normalized using a standard Gd solution. The
mean SI enhancement (% enhancement) of target tissues
(TTs) was calculated according to the following equation:
In a second set of analysis, pixels were defined enhanced
when SI was increased more than three times the SD of the
tumor signal at baseline (i.e., enhancement > 60% of the
variation seen at baseline). Student’s t test was used to
compare the differences between groups. A P value < 0.05
was considered statistically significant.
Confocal Analysis
After MRI examination, the excised tumors from group 3
mice were washed in rinse water, treated with 0.1 mol Tris
(pH 7.5) with 0.2% glycine, then dewaxed, and embedded in
paraffin wax. Serial sections (4 mm) were taken and finally
mounted on glass microscope slides (Bacto Laboratories,
New South Wales, Australia). HepG2 and B16 cells grown to
80% confluence were detached from the dishes with a
solution of trypsin (0.05%) in PBS/1 mM EDTA, washed
and maintained in suspension in serum-free medium to
recover from trypsin treatment. The cells were seeded on
glass coverslips in six-well plastic dishes (3  105 cells in
each 60-mm well) and were allowed to attach overnight at
37jC and 5% CO2 in their respective medium. The following
morning, the cells were rinsed twice in PBS and then
incubated for 24 hours in a medium containing 10% of LPDS
at 37jC. Cells were then incubated with Gd-AAZTAC17/Rhd/
LDL (30 mg/ml LDL) for 30 minutes and for 3, 8, 24, and
48 hours. After rinsing three times with PBS, the cells were
fixed with 4% formaldehyde in PBS for 10 minutes followed
by two washes with PBS. The coverslips were then permea-
bilized for 7 minutes with PBS–0.2% Triton X-100, blocked
with PBS–10% BSA for 20 minutes, and incubated with an
anti–Rab5monoclonal antibody (1:1000 in 0.1% BSA in PBS)
for 1 hour at room temperature. The cells were rinsed twice
with PBS and then incubated with an Alexa488-conjugated
rabbit anti-mouse (Molecular Probes, Milan, Italy; 1:1000) for
1 hour at room temperature. After rinsing three times with
PBS, the coverslips were air-dried and mounted with Mowiol
4-88 (Calbiochem, SanDiego, CA). Confocal microscopy anal-
ysis was performed with a confocal laser scanning microscopy
system equipped with an argon ion laser (LSM510; Zeiss,
Jena, Germany) with excitation wavelengths at 505 to 530 nm
and emission at 590 nm. All the images were taken using the
same exposure time and brightness/contrast setting. Images
of 512  512 were acquired.
Results
Relaxometric Characterization of Gd-DO3A-diph/LDL and
Gd-AAZTAC17/LDL Adducts
Gd-DO3A-diph is a new derivative of the well-known
family of GdDO3A complexes. The ligand has been synthe-
sized in a three-step reaction (Scheme 1). The obtained
ligand acts as heptadentate chelator for Gd3+ ions thus
providing a metal chelate that displays two water molecules
in the inner coordination sphere. Gd-DO3A-diph has been
characterized by measuring the proton relaxation rate of its
aqueous solutions. At a very low concentration (< 0.1 mM),
the observed relaxivity is 8.0 mM1 s1 whereas at higher
% Enhancement ¼ ððmean SI ðTTÞ postcontrast
mean SI ðTTÞ precontrastÞ
H mean SI ðTTÞ precontrastÞ  100
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concentration the linearity between the observed relaxation
rate and the actual concentration of the paramagnetic agent
is lost. This appears as a clear indication of the occurrence of
chelate self-assembly in a defined micellar-like formation.
The interaction of the two types of Gd complexes with LDL
was studied using the proton relaxation enhancement method
by measuring the relaxation rates, at 20 MHz and 25jC, of a
0.09 mM PBS solution of each complex in the presence of
increasing concentrations of LDL in PBS. Table 1 reports the
binding parameters obtained carrying out this procedure.
Both complexes showed high affinities for the lipoproteins,
whereas the relaxation enhancement of the bound forms
was rather different. This was confirmed by comparing the 1/
T1 NMRD profiles of the two adducts recorded at 25jC in
PBS (Figure 3). At any field, the relaxation rate of the solution
containing the Gd-AAZTAC17/LDL adduct is higher than that
of the Gd-DO3A-diph/LDL, whereas the relaxivities of the
two complexes in water are quite similar. The limited relax-
ation enhancement observed for the adduct with Gd-DO3A-
diph can be ascribed to the displacement of one of the two
coordinated water molecules by donor groups present on the
surface of the LDL particles. This behavior has already been
observed for other Gd-DO3A-type complexes [35]. This draw-
back is not present in the case of Gd-AAZTA-type complexes
in which the structural arrangement of the coordination cage
does not allow other donor moieties to enter the coordination
sphere and replace the bound water molecules [32,36].
Interestingly, the number of lipophilic Gd complexes that can
be bound on each LDL particle is quite different. In fact, the
linear aliphatic chain of Gd-AAZTAC17 appears more favored
in respect to the more sterically demanding substituent pres-
ent in Gd-DO3A-diph. The titrations of the solutions containing
the Gd chelates with LDL showed that each LDL particle can
load up to 400 Gd-AAZTAC17, whereas only one fourth of Gd-
DO3A-diph can be accommodated.
As far as the size of the Gd-loaded LDL particles is con-
cerned, the measured diameters of the two adducts are only
slightly higher than the diameter of the unlabelled LDL
(Table 2). This finding is taken as an indication that, under
the conditions used for preparation of the complexes, either
the lipophilic Gd complexes interact as single molecules
rather than self-assembled systems maintaining the overall
dimensions of the LDL particles on their loading with the
imaging reporters.
Uptake of Gd-DO3A-diph/LDL and Gd-AAZTAC17/LDL
Adducts into Tumor Cells
The affinity of the two LDL adducts for two different tumor
cell lines overexpressing LDLR (HepG2 and B16) [37,38] has
been assessed. To this purpose, about 1.6 million cells were
Scheme 1. Scheme of Gd-DO3A-diph synthesis.
Table 1. Proton relaxation enhancement titration of Gd-AAZTAC17 and Gd-
DO3A-diph with LDL (25jC, 20 MHz).
Adduct Ka (M
1) rb (mM
1 s1) n
Gd-AAZTAC17/LDL 1  105 22 400
Gd-DO3A-diph/LDL 5  105 12 100
The binding strength or thermodynamic association constant (Ka), the
number of binding sites (n), and the relaxivity of the macromolecular adduct
(rb) were calculated from the resultant curves.
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incubated for 16 hours at 37jC with Gd-AAZTAC17/LDL and
with Gd-DO3A-diph/LDL adducts (300:1 and 80:1 Gd/LDL
ratios, respectively; see Materials and Methods section) in
RPMI 1640 and minimum essential medium, respectively,
after 24 hours of preincubation in a medium containing 10%
of a LPDS to increase LDLRs’ expression. After incubation,
the cells were washed three times with ice-cold PBS and
detached from the culture flasks enzymatically. The relaxa-
tion rates (R1obs), measured at 7 T, of pelleted HepG2 and
B16 treated with Gd-AAZTAC17/LDL (30 mg/ml LDL in the
incubation medium) were 1.16 and 0.85 s1, respectively.
Conversely, in the presence of the same amount of Gd-
DO3A-diph/LDL adduct, the R1obs (recorded at 7 T) were
significantly lower (0.52 and 0.44 s1 with HepG2 and B16,
respectively). This is a consequence of the differences in
relaxivities (as reported in the previous paragraph) and in the
overall labeling efficiency. On this basis, the more efficient
Gd-AAZTAC17/LDL was selected for further studies. Hepa-
toma and melanoma cells were incubated for 16 hours with
increasing amounts of Gd-AAZTAC17/LDL (from 10 to 60 mg/
ml), and the Gd moles taken up by the different cell lines
were determined by ICP-MS. Both cells showed a saturating
behavior, whereas the Gdmoles internalized by HepG2 were
significantly higher than those taken up by B16, as a conse-
quence of their lower LDL binding affinity (Figure 4A) [37–
39]. The amount of internalized Gd is sufficient to generate
hyperintense signals in the corresponding MR images of
both HepG2 and B16 cells (Figure 4, B and C). To demon-
strate that the uptake of Gd-AAZTAC17/LDL adduct involves
LDLRs, competition assays with free LDL were carried out.
Figure 4B shows that the uptake of the adduct by both HepG2
and B16 cells markedly decreases as the concentration of
the free LDLs added to the culture medium increases. To
Figure 3. 1/T1
1H NMRD profile (0.01–80 MHz, pH 7, and 25jC) of Gd-
AAZTAC17 (300:1) and Gd-DO3A-diph (80:1) LDL adducts. The profiles
were acquired using 0.09 mM Gd complex solution and normalized to the
relaxivity (mM1 s1).
Table 2. Light scattering measurements of native LDL, Gd-AAZTAC17/LDL,
and Gd-DO3A-diph/LDL adducts.
Compound Size (nm)
Gd-AAZTAC17 6.6 ± 0.6
Gd-DO3A-diph 5.7 ± 0.8
Native LDL 20.6 ± 1.4
Gd-AAZTAC17/LDL (300:1) 22.9 ± 0.7
Gd-DO3A-diph/LDL (80:1) 21.3 ± 0.9
Figure 4. (A) Internalization of Gd chelates in HepG2 (n) and B16 (o) on incubation for 16 hours at 37jC of ca. 2  106 cells, in the presence of increasing
concentrations of LDL adducts (10–60 g/ml). (B) Effect of the addition of unlabeled LDL to the observed proton relaxation rates (R1obs), measured at 7 T, of
HepG2 (n) and B16 (o) cellular pellets (2  106 cells) incubated for 16 hours at 37jC with Gd-AAZTAC17/LDL 15 g/ml. (C) T1-weighted spin-echo MR image
(measured at 7 T), of an agar phantom containing: unlabelled HepG2 (1), HepG2 incubated with increasing amounts of Gd-AAZTAC17/LDL: 15 g/ml LDL (2),
30 g/ml LDL (3), and 60 g/ml LDL (4). (D) T1-weighted spin-echo MR image (measured at 7 T), of an agar phantom containing: unlabelled B16 (1), B16 incubated
with increasing amounts of Gd-AAZTAC17/LDL: 15 g/ml LDL (2), 30 g/ml LDL (3), and 60 g/ml LDL (4).
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measure cell proliferation in response to Gd-AAZTAC17/
LDL, Gd-AAZTAC17, and LDL treatment, the WST-1 cell
viability assay was performed. In both cell lines, after incu-
bation with Gd-AAZTAC17/LDL complex, no relevant differ-
ence between native LDL and the Gd-AAZTAC17/LDL
adduct was observed. On the contrary, the cytotoxic and
cytostatic effect of Gd-AAZTAC17 incubated in the absence
of LDL was significantly higher. In particular, using 30 mg/ml
Gd-AAZTAC17/LDL or LDL alone, HepG2 cell viability was
85 ± 3% and 83 ± 4%, respectively, whereas it was 55 ± 7%
when the incubation was carried out in the presence of
the same concentration of Gd-AAZTAC17. The number of
viable B16 cells after overnight incubation of 30 mg/ml Gd-
AAZTAC17-LDL and LDL was 71 ± 4% and 69 ± 5%,
respectively, whereas after incubation of the same Gd-AAZ-
TAC17 concentration, it was 45 ± 4%.
In Vitro Confocal Analysis
The cell internalization of labeled LDL was confirmed
in vitro by confocal analysis. B16 and HepG2 cells were
incubated for 30 minutes at 37jC with the fluorescent Gd-
AAZTAC17/LDL/Rhd. As shown in Figure 5, A and B, a broad
rhodamine fluorescence signal throughout the membrane
and in the cytoplasm is clearly observed, indicating active
cellular uptake. Moreover, large dots resembling vesicles are
present in the cytoplasm and under the membrane (arrows),
suggesting that the probe enters the cells through an endo-
cytic route.
To confirm this hypothesis, B16 (Figure 5C) and HepG2
(Figure 5D) cells were incubated with Gd-AAZTAC17/LDL/
Rhd for 30 minutes at 37jC and then treated with an anti–
Rab5 monoclonal antibody that is specific for early endo-
somes. Fluorescein isothiocyanate– labeled endosomes
containing Rhd are well detected, as shown by the yellow-
Figure 5. Confocal analysis of B16 (A) and HepG2 (B) cells incubated with
Gd-AAZTAC17/LDL/Rhd for 30 minutes at 37jC. Rhd accumulates in the
cytoplasm or in vescicle (arrows). The incubation of B16 (C) and HepG2 (D)
cells with Rab5 to label endosomes shows many vesicles containing Rhd
(arrows). Original magnifications: A and B,  63; B and D,  40.
Figure 6. Fat-suppressed T1-weighted multislice multiecho MR images of C57BL/6 mice grafted subcutaneously with B16 melanoma cells. Images were obtained
before (A) and 8 hours after the administration of Gd-AAZTAC17 (B) and Gd-AAZTAC17/LDL (C). Arrows show the enhanced tumor region (outlined in blank). (D)
Course of SI enhancement measured in the ROI corresponding to the whole tumors and muscle from mice injected with Gd-AAZTAC17 (full and empty blue circles,
respectively) and Gd-AAZTAC17/LDL (full and empty red squares, respectively). Graph shows the standard error of the means (SEM).
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orange areas (arrows). Some vesicles that do not contain
Rhd are also observed.
In Vivo Imaging of B16 Tumor–Bearing Mice
As it is known that Gd-AAZTAC17 has a high affinity for
HSA [32] and that the latter protein is present in serum at a
high concentration (40 mg/ml), an in vitro competition study
between HSA and Gd-AAZTAC17/LDL has been carried out.
Because the relaxivity of the Gd-AAZTAC17 adduct with
HSA is about three times higher than the relaxivity of the
LDL adduct, the formation of Gd-AAZTAC17/HSA can be
followed by measuring the proton relaxation rate (R1obs) of
the solution. To this purpose, R1obs of solutions containing
Gd-AAZTAC17/LDL (300:1, prepared as described above,
0.8 mM in Gd) were measured before and after the addition
of 40 mg/ml HSA at 37jC to simulate the in vivo conditions.
The R1obs remained unchanged during the monitored period
of 3 hours after HSA addition. We can conclude that the
stability of the Gd-AAZTAC17/LDL adduct is high enough to
prevent its dissociation when injected in the blood stream.
In vivo MRI experiments were carried out on subcutane-
ous tumors models obtained by injecting B16 melanoma
cells into the right flank of adult C57BL/6 mice. Unfortunately,
the growth of inoculated HepG2 cells in nude mice did not
provide sufficient reproducibility. One week after implanta-
tion, all mice developed palpable solid tumors of 3 to
4 mm in diameter. At this time, a first group (group 1) of
animals (n = 7) received intravenously 0.06 mmol/kg of
Gd-AAZTAC17 and a second group (group 2) of animals
(n = 10) received the same dose of Gd-AAZTAC17/LDL
adduct. Fat-suppressed T1-weighted multislice multiecho
MR images were recorded before, 10 minutes after, and 8,
24, and 48 hours after the contrast administration.
Figure 6 shows MR images of a mouse before (A) and
8 hours after Gd-AAZTAC17 (B) or Gd-AAZTAC17/LDL (C )
injection. Hyperintense regions are detected in the tumor
region (C). The analysis of SI enhancement measured in the
ROI corresponding to the whole tumor showed that in all
intervals analyzed the SI enhancement of Gd-AAZTAC17/
LDL is significantly higher than that observed after the
injection of Gd-AAZTAC17 alone (Figure 7). Because the
SI is not homogenously distributed in the tumor mass, we
performed a pixel by pixel analysis, in which pixels were
classified as enhanced when SI was increased more than
three times the SD of the tumor signal at baseline (i.e.,
enhancement > 60% of the variation seen at baseline). As
shown in Figure 7, a significantly higher enhancement was
observed in Gd-AAZTAC17/LDL–treated tumors 8 hours
postinjection compared with Gd-AAZTAC17 alone (P =
.001). The SI enhancements measured in the liver, kidneys,
and muscle on administration of Gd-AAZTAC17/LDL and
Gd-AAZTAC17 alone show that the elimination of both
occurs largely through the liver. Table 3 shows the SI percent
enhancement measured 4, 24, and 48 hours after the con-
trast agent administration in liver and tumor. The liver SI
decreased 10-fold in 48 hours, thus indicating a rapid elim-
ination through the biliary system of both free and LDL-bound
Gd-AAZTAC17. The in vivo uptake of Gd-AAZTAC17/LDL
was further confirmed by immunofluorescence following
in vivo administration of LDL bearing both Gd-AAZTAC17
and a fluorescent phospholipid containing rhodamine (group
3 mice, n = 3). Group 3 mice were examined by MRI before
and 8 hours after injection, and their tumors were then
excised and analyzed by MRI. A marked percent SI en-
hancement of 90 ± 10 was detected in the central tumor
region (Figure 8, central panel ). Confocal microscopy anal-
ysis was performed on tumor serial sections (4 mm) mounted
on glass microscope slides and indicated very intense Rhd-
induced fluorescence in the hyperintense areas detected in
the MR images (panels A and B). Conversely, the rhodamine
response was weak (panel C) or completely absent in the
other areas. Histological analysis showed that Rhd ap-
pearance occurs only in the tumors from mice injected with
Gd-AAZTAC17/Rhd/LDL and not after simple injection of Gd-
AAZTAC17 or Gd-AAZTAC17/LDL (data not shown).
Discussion
The development of procedures that lead to the accumula-
tion of imaging probes at the targeting site is an important
task for molecular imaging applications. This objective is
crucial for MRI as it is less sensitive with respect to other
imaging modalities. To this purpose, among the different
classes of Gd-based systems, it is fundamental to use
complexes endowed with the highest sensitivity compatible
with the resulting thermodynamic stability. GdDO3A and
Figure 7. Plot of MRI SI enhancement obtained considering tumor pixels
where the signal is 3 SD more intense than the pre contrast tumor intensity.
Significantly higher enhancement was observed 8 hours postinjection of Gd-
AAZTAC17/LDL (blue) compared with Gd-AAZTAC17 alone. Graph shows
the standard error of the means (SEM). **P = .001.
Table 3. Percent enhancement measured after the injection of Gd-AAZTAC17 and Gd-AAZTAC17/LDL adduct.
Tissue 4 hours (%) 24 hours (%) 48 hours (%)
Gd-AAZTAC17 Gd-AAZTAC17/LDL Gd-AAZTAC17 Gd-AAZTAC17/LDL Gd-AAZTAC17 Gd-AAZTAC17/LDL
Liver 207 ± 27 280 ± 23 78 ± 16 84 ± 15 37 ± 14 23 ± 7
Tumor 22 ± 5 42 ± 9 5 ± 3 13 ± 4 4 ± 1 10 ± 1
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GdAAZTA have a relaxivity approximately 60% higher than
the octadentate standard contrast agents (i.e., GdDOTA,
GdHPDO3A, GdDTPA, and GdDTPA-BMA) because they
contain two water molecules coordinated to the Gd3+ ion.
Furthermore, both complexes are thermodynamically stable.
For these reasons, these complexes have been selected for
conjugation with hydrophobic groups to pursue the binding
to LDL and use the resulting adducts as carriers to address
tumor cells overexpressing LDLRs. The relaxivity enhance-
ment observed after binding with LDL, due to the increase
of the tumbling time of the macromolecular adduct, is more
pronounced for the GdAAZTA- than for the GdDO3A-
containing system. In fact, in the latter, the coordinated water
molecules are partially replaced by donor groups from the
protein or from phospholipids present on the LDL surface.
This drawback that is often encountered for Gd(III) chelates
containing two coordinated water molecules does not occur
with Gd-AAZTA derivatives because the solution structure
of Gd-AAZTA does not allow the replacement of the coordi-
nated water molecules from other substrates [36]. MRI
detection of the cellular uptake of LDL labeled with Gd-
AAZTAC17 was shown in vitro on HepG2 and B16 cell lines,
and competition studies demonstrated that this uptake is
driven by LDLRs. The integrity of the adducts is maintained
also in the presence of many competitor species to outline
the overall stability of these systems. Interestingly, the inter-
calation of about 300 Gd complexes into the LDL particle
does not change its affinity for its receptor although the
negative charge of the complexes could partially neutralize
the positively charged amino acid sequence involved in the
binding to LDLR. Confocal analysis of B16 and HepG2 cells
incubated with Gd-AAZTAC17/LDL/Rhd showed that the
probe enters the cells and colocalizes in the endosome/
lysosome compartment. MRI analysis performed in vivo on
C57BL/6 mice grafted with melanoma B16 cells showed a
good tumor SI enhancement (30–40%), 8 hours after the
injection of Gd-AAZTAC17/LDL adduct, significantly higher
than that measured after the injection of the Gd-AAZTAC17
alone. An important finding deals with the intratumor locali-
zation of the imaging probe. In fact, its enhanced accumula-
tion could be the effect of the binding with the target receptors
on nonendothelial cells or only the consequence of the in-
creased permeability of tumor vessel (enhanced permeability
and retention [EPR]). The intracellular localization evidenced
by confocal analysis on excised tumors gives support to the
view that the accumulation of the imaging probe in the tumor
region is the result of an enhanced cell uptake. However, more
in vivo competition studies with native LDL have to be per-
formed to get a better insight on the determinants of the en-
hanced uptake of Gd-AAZTAC17/LDL adducts in the tumor
region. Furthermore, nonspecific uptake could be investigated
using tumors that do not express LDLR [21].
The capability of LDL to deliver different compounds
inside the targeted cells may be exploited for developing
efficient antitumor treatments. In fact, the pharmacological
activity can be largely improved by an intracellular drug
delivery. Furthermore, the loading of LDL with both Gd-
AAZTAC17 and an antitumor drug makes possible for the
direct MR imaging and quantification of drug delivery. The
drawback of the association with normal tissues expressing
LDLR can be overcome by rerouting labeled LDL particles to
other selected receptors as shown in the works of Zheng
et al. [20] and Chen et al. [28]. This was carried out conju-
gating folate-containing groups to the exposed lysines on
ApoB100, responsible of the selective binding to LDLR.
In summary, as anticipated in the study of Corbin et al.
[29], LDLs act as efficient carriers for the delivery of the
lipophilic Gd complexes to tumor cells. Gd-AAZTAC17 dis-
plays a much higher sensitivity than Gd-DO3A-diph and any
previously reported system and appears an excellent candi-
date for further structural modifications that may still improve
the use of the high-capacity LDL receptors as in vivomarkers
of tumor cells.
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